Brilaroxazine hydrochloride is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Major Depressive Disorder.

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...

Current treatments are estimated to only reduce about one-third of the disease burden of depressive disorders. Prevention may be an alternative strategy to further reduce the disease burden of ...

Once you get treatment for mania ... While bipolar disorder can cause a depressed mood, bipolar disorder and depression have one major difference. With bipolar disorder, you might have “up ...

Depression, which doctors may call major depressive disorder, is a treatable mental ... test to see if you have it and help you manage and treat it. By far, insomnia is the most common sleep ...

If you’ve been diagnosed with clinical depression, also known as major depressive disorder (MDD), rest assured there are many treatment options available. Some people will experience only one ...

A mental health professional familiar with cognitive remediation would be the best guide for group treatment. Do you live with major depressive disorder? Learn about the resources and protections ...

The proportion of people with major depressive disorder receiving minimally adequate treatment by country, 2021. Credit: The Lancet Psychiatry (2024). DOI: 10.1016/S2215-0366(24)00317-1 ...